



vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer's Disease

11/13/17

HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 13, 2017-- [vTv Therapeutics Inc.](http://www.vtvtherapeutics.com) (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer's disease in New York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET.

The event will feature two speakers, each with extensive experience in the clinical development in Alzheimer's:

- Dr. Howard Fillit, founding executive director and chief scientific officer of Alzheimer's Drug Discovery Foundation, clinical professor of geriatric medicine, palliative care, and neuroscience at Mt. Sinai School of Medicine
- Dr. Mary Sano, associate dean for clinical research, professor of Psychiatry, founding member and director of the Alzheimer's Disease Research Center at Mt. Sinai School of Medicine

In addition to the presentations, vTv Therapeutics will provide a brief overview of the company's ongoing Phase 3 clinical development program for azeliragon, an orally bioavailable small molecule RAGE antagonist for patients with mild Alzheimer's disease.

To register to attend the event, contact Mike Biega, Trout Group: mbiega@troutgroup.com or register [here](#). Advanced registration is required, as space is limited.

A live webcast of the event will be available on the Investor page of vTv's website at www.vtvtherapeutics.com. The archived version of the webcast will be available for replay on the [Events & Presentations](#) section of the Investors page of vTv Therapeutics' website for 90 days following the event.

About Azeliragon

vTv discovered and developed azeliragon using its proprietary drug discovery platform TTP Translational Technology®. A broad range of human pathologic and experimental biologic investigation suggests that RAGE activation contributes to the pathogenesis of Alzheimer's disease. Sustained Amyloid- β interactions with RAGE at the blood-brain barrier (BBB) and in neuronal and microglial cells, play potentially major roles in amyloid plaque formation, neuroinflammation and chronic neural dysfunction – all hallmarks of Alzheimer's disease. Azeliragon, also known as TTP488, is a novel orally active small-molecule antagonist of RAGE.

About STEADFAST

STEADFAST, two identical randomized, double-blind, placebo-controlled Phase 3 trials, is investigating the safety and efficacy of azeliragon as a potential treatment to slow the decline in cognition and functional activities for patients with mild Alzheimer's disease. The 18-month trial targeted enrollment of 800 patients (400 each for Part A and B). Part A enrolled patients in the United States and Canada. Enrollment of Part B additionally included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa. Subjects completing the STEADFAST study are eligible to enroll in a 24-month open-label extension trial. STEADFAST is being conducted following agreement with FDA under the Special Protocol Assessment (SPA) process and the azeliragon development program has been granted fast track designation. Enrollment of Part A was completed in September 2016 with data expected to read out in early 2018. Part B data is expected to read out in late 2018.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-

looking statements. Important factors that could cause our results to vary from expectations include those described under the heading "Risk Factors" in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171113005414/en/>

Source: vTv Therapeutics Inc.

Investors:

vTv Therapeutics Inc.

Mike Biega, 617-221-9660

IR@vtytherapeutics.com

Media:

Pure Communications

Katie Engleman, 910-509-3977

Katie@purecommunications.com